A systematic review in pharmacy and pharmacology synthesizes evidence on drug efficacy, safety, pharmacokinetics, and real-world effectiveness to support clinical decision-making, formulary management, and regulatory submissions. These reviews are essential for comparing therapeutic alternatives, evaluating adverse event profiles, and translating bench-to-bedside pharmacological findings into evidence-based prescribing guidelines.
The Regulatory Imperative Driving Pharmaceutical Evidence Synthesis
Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) increasingly require systematic reviews as part of drug approval and health technology assessment submissions. The FDA's Guidance on Systematic Review in Regulatory Submissions (2023) specifies that sponsors must use systematic, transparent methods when summarizing the evidence base for new drug applications.
The National Institute for Health and Care Excellence (NICE) in the UK mandates systematic reviews and network meta-analyses as the basis for technology appraisals that determine whether the National Health Service will fund new medications. Similar requirements exist through Canada's CADTH, Australia's PBAC, and Germany's IQWiG.
This regulatory landscape means that pharmaceutical systematic reviews must meet particularly high methodological standards. Protocol registration on PROSPERO, comprehensive search documentation, validated risk of bias assessment, and transparent statistical methods are not optional enhancements but mandatory requirements that determine whether a drug reaches patients.
Hospital pharmacy and therapeutics (P&T) committees also rely on systematic reviews when evaluating new additions to institutional formularies. A well-conducted systematic review comparing a new antibiotic against existing formulary options directly influences purchasing decisions affecting thousands of patients.
Database Strategy for Pharmaceutical Evidence
Pharmaceutical systematic reviews require searching beyond standard biomedical databases to capture the full evidence base, including unpublished regulatory data.
PubMed/MEDLINE and Embase form the core. Embase is particularly important in pharmacy because it indexes pharmacological journals, drug concentration studies, and European pharmaceutical literature not covered by MEDLINE. The Emtree drug hierarchy provides granular drug classification that MeSH does not match.
International Pharmaceutical Abstracts (IPA) captures pharmacy practice research, drug utilization studies, and pharmaceutical technology articles from pharmacy-specific journals not indexed elsewhere.
ClinicalTrials.gov and the EU Clinical Trials Register contain results data from completed trials, including those never published in journals. The FDA Amendments Act (2007) requires registration and results reporting for most drug trials, making these registries essential for addressing understanding publication bias.
FDA Orange Book, EMA European Public Assessment Reports (EPARs), and Health Canada Drug Database contain regulatory review documents with detailed efficacy and safety data from pivotal trials.
The Cochrane Drugs and Alcohol Group and Cochrane Effective Practice and Organization of Care (EPOC) maintain specialized trial registers relevant to pharmaceutical interventions. Building an effective search strategy explained across these sources requires understanding each database's controlled vocabulary for drug names, which vary between generic names, brand names, and chemical identifiers. Use our convenient search strategy builder to structure your multi-database approach.
Network Meta-Analysis for Drug Comparisons
Pharmacy systematic reviews frequently need to compare multiple drugs simultaneously when head-to-head trials are scarce. Network meta-analysis (NMA), also called mixed-treatment comparison, combines direct evidence (Drug A vs. Drug B) with indirect evidence (Drug A vs. placebo and Drug B vs. placebo) to estimate relative effects across an entire drug class.
The NICE Decision Support Unit technical support documents provide the methodological standard for network meta-analysis in pharmaceutical applications. Key considerations include:
Transitivity assumption: indirect comparisons are only valid if the studies comparing Drug A vs. placebo are similar in patient population, dose, and follow-up to those comparing Drug B vs. placebo. Violation of transitivity produces misleading results.
Consistency assessment: where direct and indirect evidence coexist, they should agree. Node-splitting models test for inconsistency at each comparison.
Ranking probabilities: network meta-analysis produces SUCRA (Surface Under the Cumulative Ranking) scores or P-scores that rank treatments by probability of being best. These rankings are useful for P&T committee decisions but should be interpreted alongside effect estimates and confidence intervals.
NMA requires specialized software, typically R packages (gemtc, netmeta, multinma) or WinBUGS/OpenBUGS for Bayesian models. Our biostatistics service provides network meta-analysis analysis using validated Bayesian and frequentist methods.